Gene profiling of Mta1 identifies novel gene targets and functions

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Ghanta, Krishna Sumanth ^a   Li, Da Qiang ^a   Eswaran, Jeyanthy ^a   Kumar, Rakesh ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; CARBONYL REDUCTASE; CD24 ANTIGEN; CD34 ANTIGEN; COLLAGENASE 3; COMPLEMENT COMPONENT C1; DECORIN; ENTACTIN; GLUTATHIONE TRANSFERASE T1; GLYCINE AMIDINOTRANSFERASE; GUANOSINE TRIPHOSPHATASE; HISTONE H1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LAMININ ALPHA4; LIPOPOLYSACCHARIDE BINDING PROTEIN; METALLOTHIONEIN II; METASTASIS ASSOCIATED PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEASOME; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PROTEIN P53; REGULATOR PROTEIN; S6 KINASE; S6 KINASE POLYPEPTIDE 6; SECRETED FRIZZLED RELATED PROTEIN 2; SERINE PROTEINASE INHIBITOR; SERUM AMYLOID A; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; MTA1 PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; EXON; FIBROBLAST CULTURE; GENE CLUSTER; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE TARGETING; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN FUNCTION; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UNINDEXED SEQUENCE; UPREGULATION; ALGORITHM; ANIMAL; CELL CULTURE; CLUSTER ANALYSIS; EMBRYONIC STEM CELL; FIBROBLAST; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENE SILENCING; GENETICS; HUMAN; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; TUMOR SUPPRESSOR GENE; VALIDATION STUDY;

MAMMALIA;

ALGORITHMS; ANIMALS; CELLS, CULTURED; CLUSTER ANALYSIS; EMBRYONIC STEM CELLS; FIBROBLASTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE KNOCKDOWN TECHNIQUES; GENE REGULATORY NETWORKS; GENES, P53; HUMANS; MICE; MICE, KNOCKOUT; MICROARRAY ANALYSIS; QUALITY CONTROL; TRANSCRIPTION FACTORS; VALIDATION STUDIES AS TOPIC;

EID: 79952177821     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017135     Document Type: Article

References (51)

1. Auboeuf D, Honig A, Berget SM, O'Malley BW, (2002) Coordinate regulation of transcription and splicing by steroid receptor coregulators. Science 298 (5592): 416-419 10.1126/science.1073734.
2. Lonard DM, O'Malley BW, (2006) The expanding cosmos of nuclear receptor coactivators. Cell 125 (3): 411-414 10.1016/j.cell.2006.04.021.
3. Lonard DM, O'malley BW, (2007) Nuclear receptor coregulators: Judges, juries, and executioners of cellular regulation. Mol Cell 27 (5): 691-700 10.1016/j.molcel.2007.08.012.
4. McKenna NJ, Cooney AJ, DeMayo FJ, Downes M, Glass CK, et al. (2009) Minireview: Evolution of NURSA, the nuclear receptor signaling atlas. Mol Endocrinol 23 (6): 740-746 10.1210/me.2009-0135.
5. Collingwood TN, Urnov FD, Wolffe AP, (1999) Nuclear receptors: Coactivators, corepressors and chromatin remodeling in the control of transcription. J Mol Endocrinol 23 (3): 255-275.
6. Martini PG, Katzenellenbogen BS, (2003) Modulation of estrogen receptor activity by selective coregulators. J Steroid Biochem Mol Biol 85 (2-5): 117-122.
7. Germain P, Staels B, Dacquet C, Spedding M, Laudet V, (2006) Overview of nomenclature of nuclear receptors. Pharmacol Rev 58 (4): 685-704 10.1124/pr.58.4.2.
8. Nagaich AK, Rayasam GV, Martinez ED, Becker M, Qiu Y, et al. (2004) Subnuclear trafficking and gene targeting by steroid receptors. Ann N Y Acad Sci 1024: 213-220 10.1196/annals.1321.002.
9. Novac N, Heinzel T, (2004) Nuclear receptors: Overview and classification. Curr Drug Targets Inflamm Allergy 3 (4): 335-346.
10. Pan Y, Tsai CJ, Ma B, Nussinov R, (2010) Mechanisms of transcription factor selectivity. Trends Genet 26 (2): 75-83 10.1016/j.tig.2009.12.003.
11. Dobrzycka KM, Townson SM, Jiang S, Oesterreich S, (2003) Estrogen receptor corepressors - a role in human breast cancer? Endocr Relat Cancer 10 (4): 517-536.
12. Hsia EY, Goodson ML, Zou JX, Privalsky ML, Chen HW, (2010) Nuclear receptor coregulators as a new paradigm for therapeutic targeting. Adv Drug Deliv Rev 10.1016/j.addr.2010.09.016.
13. Manavathi B, Singh K, Kumar R, (2007) MTA family of coregulators in nuclear receptor biology and pathology. Nucl Recept Signal 5: e010 10.1621/nrs.05010.
14. Denslow SA, Wade PA, (2007) The human mi-2/NuRD complex and gene regulation. Oncogene 26 (37): 5433-5438 10.1038/sj.onc.1210611.
15. Toh Y, Pencil SD, Nicolson GL, (1994) A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses. J Biol Chem 269 (37): 22958-22963.
16. Toh Y, Pencil SD, Nicolson GL, (1995) Analysis of the complete sequence of the novel metastasis-associated candidate gene, mta1, differentially expressed in mammary adenocarcinoma and breast cancer cell lines. Gene 159 (1): 97-104.
17. Kumar R, Wang RA, Bagheri-Yarmand R, (2003) Emerging roles of MTA family members in human cancers. Semin Oncol 30 (5) Suppl 16: 30-37.
18. Mazumdar A, Wang RA, Mishra SK, Adam L, Bagheri-Yarmand R, et al. (2001) Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 3 (1): 30-37 10.1038/35050532.
19. Molli PR, Singh RR, Lee SW, Kumar R, (2008) MTA1-mediated transcriptional repression of BRCA1 tumor suppressor gene. Oncogene 27 (14): 1971-1980 10.1038/sj.onc.1210839.
20. Gururaj AE, Singh RR, Rayala SK, Holm C, den Hollander P, et al. (2006) MTA1, a transcriptional activator of breast cancer amplified sequence 3. Proc Natl Acad Sci U S A 103 (17): 6670-6675 10.1073/pnas.0601989103.
21. Balasenthil S, Gururaj AE, Talukder AH, Bagheri-Yarmand R, Arrington T, et al. (2007) Identification of Pax5 as a target of MTA1 in B-cell lymphomas. Cancer Res 67 (15): 7132-7138 10.1158/0008-5472.CAN-07-0750.
22. Yao YL, Yang WM, (2003) The metastasis-associated proteins 1 and 2 form distinct protein complexes with histone deacetylase activity. J Biol Chem 278 (43): 42560-42568 10.1074/jbc.M302955200.
23. Li DQ, Ohshiro K, Reddy SD, Pakala SB, Lee MH, et al. (2009) E3 ubiquitin ligase COP1 regulates the stability and functions of MTA1. Proc Natl Acad Sci U S A 106 (41): 17493-17498 10.1073/pnas.0908027106.
24. Li DQ, Divijendra Natha Reddy S, Pakala SB, Wu X, Zhang Y, et al. (2009) MTA1 coregulator regulates p53 stability and function. J Biol Chem 284 (50): 34545-34552 10.1074/jbc.M109.056499.
25. Levine AJ, (1997) P53, the cellular gatekeeper for growth and division. Cell 88 (3): 323-331.
26. Maslon MM, Hupp TR, (2010) Drug discovery and mutant p53. Trends Cell Biol 20 (9): 542-555 10.1016/j.tcb.2010.06.005.
27. Wang Z, Sun Y, (2010) Targeting p53 for novel anticancer therapy. Transl Oncol 3 (1): 1-12.
28. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75 (4): 817-825.
29. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ, (1993) The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75 (4): 805-816.
30. Li DQ, Pakala SB, Reddy SD, Ohshiro K, Peng SH, et al. (2010) Revelation of p53-independent function of MTA1 in DNA damage response via modulation of the p21 WAF1-proliferating cell nuclear antigen pathway. J Biol Chem 285 (13): 10044-10052 10.1074/jbc.M109.079095.
31. Li DQ, Ohshiro K, Khan MN, Kumar R, (2010) Requirement of MTA1 in ATR-mediated DNA damage checkpoint function. J Biol Chem 285 (26): 19802-19812 10.1074/jbc.M109.085258.
32. Smeenk G, Wiegant WW, Vrolijk H, Solari AP, Pastink A, et al. (2010) The NuRD chromatin-remodeling complex regulates signaling and repair of DNA damage. J Cell Biol 190 (5): 741-749 10.1083/jcb.201001048.
33. Chou DM, Adamson B, Dephoure NE, Tan X, Nottke AC, et al. (2010) A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage. Proc Natl Acad Sci USA 107 (43): 18475-18480 10.1073/pnas.1012946107.
34. Li DQ, Kumar R, (2010) Mi-2/NuRD complex making inroads into DNA-damage response pathway. Cell Cycle 9 (11).
35. Manavathi B, Peng S, Rayala SK, Talukder AH, Wang MH, et al. (2007) Repression of Six3 by a corepressor regulates rhodopsin expression. Proc Natl Acad Sci U S A 104 (32): 13128-13133 10.1073/pnas.0705878104.
36. McMasters KM, Montes de Oca Luna R, Pena JR, Lozano G, (1996) Mdm2 deletion does not alter growth characteristics of P53-deficient embryo fibroblasts. Oncogene 13 (8): 1731-1736.
37. Sadr-Nabavi A, Ramser J, Volkmann J, Naehrig J, Wiesmann F, et al. (2009) Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer 124 (7): 1727-1735 10.1002/ijc.24108.
38. Ali A, Yang OO, (2006) A novel small reporter gene and HIV-1 fitness assay. J Virol Methods 133 (1): 41-47 10.1016/j.jviromet.2005.10.016.
39. Monaco C, Negrini M, Sozzi G, Veronese ML, Vorechovsky I, et al. (1997) Molecular cloning and characterization of LOH11CR2A, a new gene within a refined minimal region of LOH at 11q23. Genomics 46 (2): 217-222 10.1006/geno.1997.5036.
40. Gentile M, Ahnstrom M, Schon F, Wingren S, (2001) Candidate tumour suppressor genes at 11q23-q24 in breast cancer: Evidence of alterations in PIG8, a gene involved in p53-induced apoptosis. Oncogene 20 (53): 7753-7760 10.1038/sj.onc.1204993.
41. Zhou MI, Foy RL, Chitalia VC, Zhao J, Panchenko MV, et al. (2005) Jade-1, a candidate renal tumor suppressor that promotes apoptosis. Proc Natl Acad Sci U S A 102 (31): 11035-11040 10.1073/pnas.0500757102.
42. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, et al. (2005) IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434 (7034): 772-777 10.1038/nature03464.
43. Pakala SB, Bui-Nguyen TM, Reddy SD, Li DQ, Peng S, et al. (2010) Regulation of NF-kappaB circuitry by a component of the nucleosome remodeling and deacetylase complex controls inflammatory response homeostasis. J Biol Chem 285 (31): 23590-23597 10.1074/jbc.M110.139469.
44. Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, et al. (2010) Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene 10.1038/onc.2010.430.
45. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, et al. (2009) Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 6 (9): 519-527 10.1038/nrclinonc.2009.111.
46. Bild AH, Potti A, Nevins JR, (2006) Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer 6 (9): 735-741 10.1038/nrc1976.
47. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439 (7074): 353-357 10.1038/nature04296.
48. Gong Y, Somwar R, Politi K, Balak M, Chmielecki J, et al. (2007) Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med 4 (10): e294 10.1371/journal.pmed.0040294.
49. Benest AV, Augustin HG, (2009) Cancer: Blood vessels kept quiet. Nature 458 (7234): 41-42 10.1038/458041a.
50. Benson JD, Chen YN, Cornell-Kennon SA, Dorsch M, Kim S, et al. (2006) Validating cancer drug targets. Nature 441 (7092): 451-456 10.1038/nature04873.
51. Saeed AI, Sharov V, White J, Li J, Liang W, et al. (2003) TM4: A free, open-source system for microarray data management and analysis. BioTechniques 34 (2): 374-378.